The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation

Iranian Journal of Allergy, Asthma and Immunology

Volumn 11, Issue 1, 2012, Pages 15-21

  Hosseini, Ehteramolsadat ^a   Schwarer, Anthony P ^a   Ghasemzadeh, Mehran ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; HLA E polymorphisms; Overall survival

Indexed keywords

CYCLOSPORIN A; FLUDARABINE; HLA E ANTIGEN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RADIOTHERAPY; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE LOCUS; GENOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; T CELL DEPLETION; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VICTORIA; YOUNG ADULT;

EID: 84859117799     PISSN: 17351502     EISSN: 17355249     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Copelan EA. Hematopoietic stem-cell transplantation. The New England journal of medicine 2006; 354(17):1813-26.
2. Sullivan LC, Clements CS, Rossjohn J, Brooks AG. The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity. Tissue antigens 2008; 72(5):415-24.
3. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, et al. HLA-E binds tonatural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391(6669):795-9. (Pubitemid 28099678)
4. Lopez-Botet M, Bellon T. Natural killer cell activation and inhibition by receptors for MHC class I. Current opinion in immunology 1999; 11(3):301-7. (Pubitemid 29263958)
5. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Pena J, et al. Structure and function ofmajor histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Molecular immunology 2002; 38(9):637-60. (Pubitemid 34168194)
6. Sullivan LC, Hoare HL, McCluskey J, Rossjohn J, Brooks AG. A structural perspective onMHC class Ib molecules in adaptive immunity. Trends in immunology 2006; 27(9):413-20. (Pubitemid 44216194)
7. Tripathi P, Naik S, Agrawal S. HLA-E and immunobiology ofpregnancy. Tissue antigens 2006; 67(3):207-13.
8. Hodgkinson AD, Millward BA, Demaine AG. The HLAE locus isassociated with age at onset and susceptibility to type 1 diabetes mellitus. Human immunology 2000; 61(3):290-5. (Pubitemid 30117796)
9. Lajoie J, Hargrove J, Zijenah LS, Humphrey JH, Ward BJ, Roger M. Genetic variants innonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. The Journal of infectious diseases 2006; 193(2):298-301. (Pubitemid 43113493)
10. Park KS, Park JS, Nam JH, Bang D, Sohn S, Lee ES. HLA-E*0101 and HLA-G*010101 reduce the risk of Behcet's disease. Tissue antigens 2007; 69(2):139-44. (Pubitemid 46174868)
11. Chan SH, Chew CT, Prasad U, Wee GB, Srinivasan N, Kunaratnam N. HLA and nasopharyngeal carcinoma in Malays. British journal of cancer 1985; 51(3):389-92. (Pubitemid 15132688)
12. Ren EC, Chan SH. Human leucocyte antigens and nasopharyngeal carcinoma. Clin Sci (Lond) 1996; 91(3):256-8. (Pubitemid 26305912)
13. Tamouza R, Busson M, Rocha V, Fortier C, Haddad Y, Brun M, et al. Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation. Transplantation 2006; 82(11):1436-40. (Pubitemid 44967625)
14. Danzer M, Polin H, Proll J, Haunschmid R, Hofer K, Stabentheiner S, et al. Clinical significance ofHLAE*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation. Transplantation 2009; 88(4):528-32.
15. Grimsley C, Kawasaki A, Gassner C, Sageshima N, Nose Y, Hatake K, et al. Definitive high resolution typing of HLA-E allelic polymorphisms: Identifying potential errors in existing allele data. Tissue antigens 2002; 60(3):206-12. (Pubitemid 35398823)
16. Kanai T, Fujii T, Keicho N, Tokunaga K, Yamashita T, Hyodo H, et al. Polymorphism ofhuman leukocyte antigen-E gene in the Japanese population with or without recurrent abortion. Am J Reprod Immunol 2001; 45(3):168-73. (Pubitemid 32156568)
17. Grimsley C, Ober C. Population genetic studies ofHLAE: evidence for selection. Human immunology 1997; 52(1):33-40. (Pubitemid 27053844)
18. Steffensen R, Christiansen OB, Bennett EP, Jersild C. HLA-E polymorphism inpatients with recurrent spontaneous abortion. Tissue antigens 1998; 52(6):569-72. (Pubitemid 29002761)